Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 391-396

  Umeguchi, Hitomi ^a   Sueoka Aragane, Naoko ^a   Kobayashi, Naomi ^a   Nakamura, Tomomi ^a   Sato, Akemi ^a   Takeda, Yuji ^a   Hayashi, Shinichiro ^a   Sueoka, Eisaburo ^b   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

HGF; Lung cancer; Monitoring system; Plasma; T790M

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; SCATTER FACTOR; BIOLOGICAL MARKER; EGFR PROTEIN, HUMAN; HGF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; DRUG RESPONSE; EGFR GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; SMOKING; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84916217805     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3560     Document Type: Article

References (31)

1. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
2. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
3. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
4. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
6. Zakowski MF, Ladanyi M and Kris MG: Memorial sloan-kettering cancer center lung cancer oncogenome group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355: 213-215, 2006.
7. Yano S, Wang W, Li Q, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487, 2008.
8. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711, 2008.
9. Wang W, Li Q, Takeuchi S, et al: Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18: 1663-1671, 2012.
10. Nakagawa T, Takeuchi S, Yamada T, et al: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11: 2149-2157, 2012.
11. Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13: 528-538, 2012.
12. Katakami N, Atagi S, Goto K, et al: LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31: 3335-3341, 2013.
13. Sequist LV, Pawel J, Garmey EG, et al: Randomised phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29: 3307-3315, 2011.
14. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al: A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 6: 1639-1648, 2011.
15. Yano S, Yamada T, Takeuchi S, et al: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6: 2011-2017, 2011.
16. Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240-2247, 2013.
17. Mizuno S and Nakamura T: HGF-MET cascade, a key target for inhibiting cancer metastasis: The impact of NK4 discovery on cancer biology and therapeutics. Int J Mol Sci 14: 888-919, 2013.
18. Jiang WG, Martin TA, Parr C, et al: Hepatocyte growth factor, its receptor and their potential value in cancer therapies. Crit Rev Oncol Hematol 53: 35-69, 2005.
19. Martin TA, Parr C, Davies G, et al: Growth and angiogenesis of human breast cancer in a nude mouse tumor model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24: 1317-1323, 2003.
20. Wisles M, Rabbe N, Marchal J, et al: Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor progression and death. Cancer Res 63: 1405-1412, 2003.
21. Grenier A, Chollet-Martin S, Crestani B, et al: Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 99: 2997-3004, 2002.
22. Goldstrow P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
23. Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28: 357-360, 2010.
24. Takanami I, Tanana F, Hashizume T, et al: Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Oncology 53: 392-397, 1996.
25. Siegfried JM, Weissfeld LA, Luketich JD, et al: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66: 1915-1918, 1998.
26. Toiyama Y, Miki C, Inoue Y, et al: Serum hepatocyte growth factor as a prognostic marker for stage I or II colorectal cancer patients. Int J Cancer 125: 1657-1662, 2009.
27. Tanaka K, Miki C, Wakuda R, et al: Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 8: 754-760, 2004.
28. Gupta A, Karakiewicz PI, Roehrborn CG, et al: Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 14: 7385-7390, 2008.
29. Seidel C, Borset M, Turesson I, et al: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91: 1806-1812, 1998.
30. Arcila MA, Oxnard GR, Nafa K, et al: Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17: 1169-1180, 2011.
31. Suda K, Murakami I, Katayama, et al: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16: 5489-5498, 2010.